Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis | Synapse
March 3, 2026
Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis
Puntos clave
Real-world efficacy of enfortumab vedotin matches outcomes of eligible patients in the EV-301 trial.
Ineligible patients demonstrated statistically inferior outcomes compared to those who qualified for the trial.
Bayesian restricted mean survival time analysis across multiple centers provides robust data.
Findings highlight the potential therapeutic impact of enfortumab vedotin in broader patient populations.
Resumen
EV exhibited real-world efficacy in Japanese mUC patients comparable to the eligible patients' outcomes in the EV-301 trial. Ineligible patients showed statistically inferior outcomes.